Nevirapine 200 mg Tablets

Nevirapine 200 mg tablets are oral non-nucleoside reverse transcriptase inhibitor (NNRTI) medicines used with other antiretroviral medicines to treat HIV-1. For this product, we offer one strength and dosage form in eight package quantities, from 20 to 360 tablets. The practical comparison is therefore between current price, quantity, expected use and how often you may need to reorder. Any choice must remain consistent with the regimen prescribed and monitored by your HIV specialist.

Available packs and per-tablet value

The comparison below presents the package quantities, current prices and per-tablet values we offer. It provides a direct way to compare financial value without treating the lowest unit price as the only consideration.

A larger package may cost less per tablet, but that does not automatically make it the appropriate choice. Nevirapine is part of a specialist-managed treatment programme, and quantity should reflect the prescribed schedule, the period before the next clinical review and whether treatment may change. A smaller package may be more practical when a regimen is being reviewed, while a larger quantity may reduce reorder frequency for an established regimen.

• Check the required quantity against the dose and duration confirmed by your HIV team.
• Consider whether you can use the tablets before the expiry date shown on the supplied package.
• Allow enough time to reorder before your existing supply runs out.
• Do not buy surplus tablets solely to obtain a lower per-tablet price.

The package-value comparison should support a medically appropriate decision rather than replace prescribing advice.

How do strength and quantity shape the choice?

Our current Nevirapine product is a 200 mg oral tablet. We do not offer a choice of strength or pharmaceutical form within this product listing, so the available decision concerns package quantity. The 200 mg strength must not be divided, substituted or treated as interchangeable with a different nevirapine formulation unless the prescribing specialist specifically directs that change.

Adult nevirapine treatment commonly includes a 14-day lead-in period of 200 mg once daily before the specialist-directed maintenance schedule begins. This lead-in is a medical safety measure intended to reduce the frequency of rash; it is not simply a purchasing format. A package should not be selected on the assumption that it represents a complete lead-in or continuation supply without first checking the prescribed directions.

When comparing quantities, consider:

• the exact daily schedule on the prescription or dispensing label;
• the date of the next HIV clinic or monitoring appointment;
• whether the regimen has recently started or changed;
• how many tablets are already available at home; and
• the expiry date and required storage conditions.

Never extend, shorten or otherwise change the treatment schedule to make it fit a particular package size. Interruptions and inconsistent use can contribute to treatment failure and the development of viral resistance.

Brand and generic context

Nevirapine is both the active ingredient and the published name of this generic product. Viramune is a brand name for a medicine containing the same active ingredient. Sharing an active ingredient does not mean that every presentation is identical: manufacturers may use different inactive ingredients, package designs and patient leaflets. Follow the information supplied with the exact product you receive, particularly if you have allergies or intolerances to excipients.

Other NNRTIs include efavirenz, rilpivirine, etravirine and doravirine. They act on the same viral enzyme but differ in dosing, resistance patterns, adverse effects and interactions. They are not direct substitutes for nevirapine without specialist review.

Readers comparing a wider treatment plan can visit our HIV category or the broader Anti Viral & Immunity range. Products such as Combivir and Epivir contain different antiretroviral ingredients and must be used only as directed within a complete specialist-prescribed regimen.

Established role in HIV treatment

Nevirapine is used in combination antiretroviral therapy for HIV-1 infection. It must not be used as the only active HIV medicine because the virus can develop resistance rapidly when treatment does not contain enough fully active agents. A specialist normally selects the complete regimen after considering treatment history, resistance results, viral load, CD4 count, liver health, other conditions and possible interactions.

The aim of combination treatment is sustained suppression of HIV replication. Effective treatment can reduce viral load and help the immune system recover, but nevirapine does not cure HIV. Continuing every component of the regimen as prescribed is important even when the person taking it feels well.

Starting nevirapine requires particular care. The risk of symptomatic liver reactions can be greater at higher CD4 counts, especially in women, so the HIV team considers the expected benefit and individual risk before initiation. Nevirapine is contraindicated in severe hepatic impairment. Liver tests and skin monitoring are particularly important during the first 18 weeks, when serious reactions are most likely to occur.

How does nevirapine work and how is it taken?

HIV uses an enzyme called reverse transcriptase to copy its genetic material. Nevirapine binds to this enzyme at a site separate from its active site and reduces its ability to function. This disrupts viral replication when nevirapine is combined with other effective antiretroviral medicines.

Nevirapine tablets are taken by mouth and may generally be taken with or without food. Follow the dispensing label and the patient information leaflet for the exact product supplied. The usual adult initiation schedule includes 200 mg once daily for the first 14 days, followed by the maintenance schedule prescribed by the HIV specialist. The lead-in period must not be extended without clinical advice, and the dose must not be increased if a rash develops during that period.

Take each dose at the scheduled time. If a dose is missed, consult the supplied leaflet or contact the HIV team or a pharmacist rather than doubling the next dose. If nevirapine has been interrupted for more than seven days, specialist advice is needed before restarting because the lead-in schedule may need to be repeated.

Do not stop nevirapine or any other component of an HIV regimen independently. An unplanned interruption can allow viral replication to resume and may limit future treatment options. If swallowing tablets is difficult, ask the prescriber or pharmacist about an appropriate authorised formulation rather than crushing or changing the tablet without advice.

Important safety considerations and interactions

The most significant early risks associated with nevirapine are severe liver injury and serious skin or hypersensitivity reactions. Liver enzymes are monitored closely during early treatment, especially during the first 18 weeks. Seek urgent medical advice for symptoms such as yellowing of the skin or eyes, dark urine, persistent nausea, abdominal pain, marked tiredness or loss of appetite.

Rash is relatively common, but a rash accompanied by fever, blistering, peeling skin, mouth ulcers, facial swelling, breathing difficulty or general illness requires urgent assessment. Severe reactions can include Stevens-Johnson syndrome, toxic epidermal necrolysis and drug reaction with eosinophilia and systemic symptoms (DRESS). Nevirapine must not be restarted after a severe rash, hypersensitivity reaction or clinically significant liver reaction attributed to the medicine.

• Tell the HIV team and pharmacist about every prescription medicine, non-prescription medicine and herbal product being used.
• Nevirapine affects liver enzymes and can alter the concentrations of other medicines, including some hormonal contraceptives and certain medicines for infections.
• St John's wort can reduce nevirapine concentrations and should not be taken with it.
• Blood glucose and lipid monitoring may be relevant for people with diabetes or other metabolic risks.
• Fatigue can occur. Do not drive or operate machinery if affected.
• Pregnancy requires coordinated specialist HIV and antenatal care because treatment benefits and liver-related risks must be assessed individually.
• Nevirapine passes into breast milk. Follow the specialist advice given about infant feeding and prevention of postnatal HIV transmission.

Children can receive nevirapine under specialist care, but dosing depends on age and body size. A 200 mg tablet is not suitable for every child and must not be selected solely because that strength is available.

Is nevirapine prescription-only in the UK?

Yes. Nevirapine is a prescription-only medicine in the United Kingdom and should be prescribed within specialist HIV care. That legal classification and the need for clinical supervision apply regardless of package size, manufacturer or ordering route.

Our current ordering process does not require customers to submit a prescription to us. Our policy does not alter the medicine's UK prescription-only status and must not be treated as permission to start, restart or change nevirapine without a valid specialist prescription. Order only the product, strength and quantity that correspond to the treatment authorised by your HIV team.

Our pharmacist-supported team is available 24/7 by email, online chat and phone to answer product and ordering questions. Questions about changing a dose, managing a serious reaction or selecting a different HIV medicine should be referred to the treating HIV service. Suspected adverse reactions can also be reported through the MHRA Yellow Card scheme.

Ordering and receiving the tablets

Before placing an order, confirm that the selected item is Nevirapine 200 mg tablets and check the required package quantity against the prescribed regimen. Enter the delivery address and UK postcode carefully during checkout. We provide the package options and current prices shown in the comparison element, while our support team can help with questions about the ordering process.

1. Select Nevirapine 200 mg tablets and the medically appropriate package quantity.
2. Review the product, quantity, price and delivery details before submitting the order.
3. Retain the order confirmation so that the details can be checked if you contact our support team.
4. On receipt, confirm that the medicine name, strength, dosage form and quantity match the order and prescribed treatment.
5. Read the patient information leaflet for the exact manufacturer and presentation supplied.

Do not take tablets if the package appears damaged, the label does not match the expected medicine or the expiry date has passed. Contact our support team about an order discrepancy, and seek advice from a pharmacist or the HIV team before using an unfamiliar presentation.

Store the tablets at 20°C to 25°C; excursions from 15°C to 30°C are permitted. Keep the bottle tightly closed and protect it from moisture. Store the medicine out of the sight and reach of children, and do not use bathroom or kitchen locations where heat or humidity may fluctuate substantially.

A balanced package-value decision

The appropriate package combines financial value with medical suitability. The per-tablet comparison can show how cost varies by quantity, but the lowest unit price should not override the prescribed regimen, upcoming monitoring, possible treatment changes, available storage or the expiry date.

• Confirm the 200 mg tablet strength and oral dosage form.
• Match the quantity to the current specialist-prescribed schedule.
• Consider the next clinical review before ordering a long-term supply.
• Plan the next order early enough to avoid an interruption.
• Store the tablets within the stated temperature range and protect them from moisture.
• Ask our pharmacist-supported team about product or ordering details, and direct treatment changes to the HIV specialist.

Using the current package-value comparison alongside the prescribed treatment plan provides a more useful basis for choosing than package price alone. It supports an informed quantity decision without encouraging unnecessary surplus or an unsupervised change to HIV therapy.